Carmell Total Cash From Financing Activities from 2010 to 2024

CTCX Stock   0.30  0.02  7.14%   
Carmell Therapeutics Total Cash From Financing Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Financing Activities will likely drop to about 5.8 M in 2024. During the period from 2010 to 2024, Carmell Therapeutics Total Cash From Financing Activities regression line of annual values had r-squared of  0.36 and arithmetic mean of  2,326,138. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
2010-12-31
Previous Quarter
11.2 M
Current Value
5.8 M
Quarterly Volatility
2.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 844.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.78. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Carmell Therapeutics Correlation against competitors.
For more information on how to buy Carmell Stock please use our How to Invest in Carmell Therapeutics guide.

Latest Carmell Therapeutics' Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Carmell Therapeutics over the last few years. It is Carmell Therapeutics' Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carmell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Slightly volatile
   Total Cash From Financing Activities   
       Timeline  

Carmell Total Cash From Financing Activities Regression Statistics

Arithmetic Mean2,326,138
Geometric Mean1,658,043
Coefficient Of Variation118.98
Mean Deviation1,809,318
Median1,195,314
Standard Deviation2,767,666
Sample Variance7.7T
Range10M
R-Value0.60
Mean Square Error5.3T
R-Squared0.36
Significance0.02
Slope371,629
Total Sum of Squares107.2T

Carmell Total Cash From Financing Activities History

20245.8 M
202311.2 M
20223.6 M

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Financing Activities11.2 M5.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.